TABLE 1.
Baseline demographics and clinical characteristics
| CD, n = 42 | UC/IBDU, n = 10 | |
|---|---|---|
| Male sex, No. (%) | 21 (50) | 2 (20) |
| Age at diagnosis, median [IQR] years | 10.3 [7.7–13.3] | 13.9 [9.9–14.8] |
| Age at UST initiation, median [IQR], years | 16.9 [13.9–18.2] | 15.2 [11.1–17] |
| Duration of disease, median [IQR], years | 4.9 [2.6–8.3] | 1.8 [0.7–3.3] |
| Disease behavior, No. (%) | ||
| Non-stricturing (B1) | 37 (88.1) | – |
| Stricturing (B2) | 3 (7.1) | – |
| Penetrating (B3) | 2 (4.8) | – |
| Perianal perforating | 5 (11.9) | – |
| CD Disease location, No. (%) | ||
| Ileal (L1) | 8 (19) | – |
| Colonic (L2) | 13 (31) | – |
| Ileocolonic (L3) | 19 (45.2) | – |
| Upper tract (L4) | 22 (52.4) | – |
| Perianal (p) | 5 (11.9) | – |
| UC/IBDU disease location, No. (%) | ||
| Proctitis (E1) | – | 1 (10) |
| Left-sided (E2) | – | 1 (10) |
| Extensive (E3) | – | 4 (40) |
| Pancolitits (E4) | – | 4 (40) |
| Concomitant IMM at UST start, No. (%) | 10 (23.8) | 2 (20) |
| Concomitant Steroids at UST start, No. (%) | 21 (50) | 7 (70) |
| Prior anti-TNF agents, No. (%) | ||
| 0 | 9 (21.4) | 1 (10) |
| 1 | 33 (79) | 9 (90) |
| 2 | 15 (35.7) | 3 (30) |
| Time from last anti-TNF to UST, median [IQR], weeks | 10.4 [6.1–97.6] | 11 [3.7–34] |
| <30 days | 6 | 3 |
| 30 to 60 days | 9 | 1 |
| 61 to 90 days | 2 | 1 |
| >90 days | 16 | 4 |
| Prior vedolizumab, No. (%) | 12 (28.6) | 7 (70) |
| Time from VDZ to UST, median [IQR], weeks | 6 [5.2–6.9] | 3 [2.5–3.7] |
| Harvey Bradshaw Index, median [IQR] | 2 [0.25–6] | – |
| Partial Mayo Score, median [IQR] | – | 8 [6.9–9] |
| CRP abnormal No. (%) | 16 (38) | 2 (20) |
| CRP (xULN), median [IQR] | 0.6 [0.2–1.7] | 0.3 [0.2–0.5] |
| Albumin, median [IQR], g/L | 38 [35–40] | 37 [35–39] |
| Haematocrit, median [IQR], L/L | 0.38 [0.35–0.41] | 0.37 [0.36–0.38] |
| Psoriasiform rash | 12 (28.6) | 1 (10) |
CD = Crohn disease; CRP = C-reactive protein; IBDU = IBD-unclassified; IMM = immunomodulator; IQR = interquartile range; TNF = tumor necrosis factor; UC = ulcerative colitis; ULN = upper limit of normal; UST = ustekinumab; VDZ = vedolizumab.